Biogen reports Phase Ib extension data for aducanumab in AD

Biogen Inc. (NASDAQ:BIIB) reported 24- and 36-month data from a long-term extension of the Phase Ib PRIME trial to treat prodromal or mild Alzheimer’s disease showing that aducanumab (BIIB037) continued to reduce amyloid plaque levels, and, according to the company, suggest a continued benefit on the rate of cognitive decline, especially at the highest doses of aducanumab compared to patients who received placebo in the first year of the trial. The company presented the data at the Clinical Trials on Alzheimer’s Disease meeting in Boston.

The double-blind, placebo-controlled, 54-week, U.S. PRIME trial evaluated once-monthly fixed doses of 1, 3, 6 and 10 mg/kg IV aducanumab as well as dose-titrated aducanumab in 196 patients with prodromal or mild AD. Data from the long-term extension included 143 patients who continued aducanumab treatment or were switched from placebo to aducanumab. Patients who received placebo in Phase Ib trial were switched to 3 mg/kg aducanumab or aducanumab titrated from 3 to 6 mg/kg or from 1 to 3 to 6 to 10 mg/kg. Patients treated with 1 mg/kg aducanumab were switched to 3 mg/kg aducanumab or dose titration to 3 to 6 mg/kg aducanumab in the extension...